Source comparison
CJC-1295 no DAC & Ipamorelin 20s Age Specific Protocol: Comparison
Mechanism GHRH analog; binds anterior pituitary GHRH receptors Selective GHS-R1a agonist; mimics ghrelin GH-release pathway Dual-pathway stimulation via GHRH + ghrelin pathways Synergistic effect produces 200–300% higher GH peak than either peptide alone Half-
This comparison does not assign a generated winner or score.
- Mechanism
- GHRH analog; binds anterior pituitary GHRH receptors
- Selective GHS-R1a agonist; mimics ghrelin GH-release pathway
- Dual-pathway stimulation via GHRH + ghrelin pathways
- Synergistic effect produces 200–300% higher GH peak than either peptide alone
- Half-Life
- ~30 minutes
- ~2 hours
- N/A
- CJC clears rapidly; Ipamorelin extends pulse duration without prolonged elevation
- Cortisol/Prolactin Impact
- Minimal
- None (highly selective)
- None
- Critical advantage over GHRP-2/6 in younger populations sensitive to hormonal side effects
- Typical Dose (20s)
- 100–150 mcg per injection
- Combined at same dose per injection
- Lower than doses required in 40+ populations due to higher receptor sensitivity
- Optimal Timing
- Pre-sleep or AM fasted
- Pre-sleep primary; AM fasted secondary
- Aligns with circadian GH peaks; avoids interference with endogenous pulsatility
- Cycle Duration
- 8–12 weeks
- 8–12 weeks with 4-week washout
- Prevents receptor desensitization and preserves natural GH secretion long-term